Business Wire

Medidata Solutions Broadens CRO Partner Accreditations to Field Increasing Product Demand

Share
NY-MEDIDATA-SOLUTIONS

Addition of Seven Accreditation Options Enables Services Partners to Support Wide Range of Medidata Clinical Research Technologies

Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that it has expanded its accreditation program for services partners to include seven additional Medidata products, in response to the increasing global demand for its product portfolio. The accreditations are available through the Medidata Partner Program, which selects and enables leading contract research organizations (CROs) and other service providers to manage sponsors’ clinical trials using Medidata products.

Since 2007, Medidata has offered partner accreditations for its Medidata Rave ® electronic data capture (EDC) and clinical data management (CDM) system, providing end user training, user and site administration, study build, reporting, outputs and migration services. With the growing number of global research sponsors implementing a range of Medidata products across the clinical development process, Medidata added the following accreditation options for Medidata Services Partners :

  • Medidata Balance ™— Partners are enabled to provide randomization and trial supply management (RTSM) services using this innovative system. Investigators can access one system—Medidata Rave—for EDC, randomization and supply management.
  • Medidata Coder ™— Partners offer medical coding services using this centralized enterprise coding solution that is easily integrated with any source system for accelerated coding activities.
  • Medidata CTMS ™— Partners can offer trial management services using modular and flexible tools for study planning, start-up and conduct, along with financial management and trial monitoring. Sponsors benefit from faster site payments, more timely monitor reporting and better visibility into trial milestones.
  • Medidata Designer ® Partners offer study design services leveraging this innovative study and protocol design solution based on reusable libraries and structured design information to improve protocol quality, expedite EDC setup and reduce amendments.
  • Medidata Grants Manager ® Partners use this trial budgeting tool for exclusive access to the PICAS®  database of negotiated costs from investigator grants to rapidly provide customers with accurate trial forecasts and budgets for clinical trials.
  • Medidata Rave Safety Gateway Partners automate their customers’ EDC-to-safety-system data transfers using this system to expedite case triage with improved accuracy and completeness of SAE case data, reduce data reconciliation activities and eliminate error-prone phone, paper and fax processes.
  • Medidata Rave Targeted SDV Partners can offer more efficient monitoring services using this EDC-based solution to execute targeted (risk-based) source document verification.

“As we continue to develop and enhance our product portfolio, there is a growing need to provide outsourcing organizations with the flexibility to add services that best complement their capabilities,” said Graham Bunn, vice president of partnerships, Medidata Solutions. “With these new accreditations, we can better enable our partners to provide greater value to sponsors on their outsourcing services, ultimately strengthening their strategic relationships.”

Medidata trains, accredits and supports Medidata Services Partners on its technology so partners can cost-effectively implement and use Medidata products for sponsors’ studies, allowing them to quickly realize the benefits of this technology. To become accredited, an organization must first complete required training with a Medidata services team to learn best practices for implementing and using the product. After demonstrating know-how and experience with specific products, Medidata recognizes the organization as a Medidata Services Partner.

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer services in support of Medidata products. Since then, the program has grown to include about 30 partners, ranging from smaller clinical consultancies to large, global CROs.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Contact:

Lois Paul & Partners
Susan McCarron, 617-986-5767
Susan_McCarron@lpp.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Allianz Announces Excellent Performance and Is Fully on Track for Full-year Ambitions7.8.2025 07:13:00 CEST | Press release

2Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806235547/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Allianz achieves strong growth and record operating profitTotal business volume rises 8.01 percent to 44.5 billion euros, supported by good growth across all segments Operating profit increases 12.2 percent and reaches a record level of 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 17.3 percent and reaches 3.0 billion euros. Adjusted for the 0.3 billion euros disposal gain on the UniCredit Joint Venture, shareholders’ core net income increases 7.1 percent 6M 2025 Excellent performance across our businesses and record operating profitTotal business volume grows 10.1 1 percent and reaches 98.5 billion euros, with contributions from all segments Operating profit increases 9.3 percent to 8.6 billion euros, our highest half-

New pulp mill boosts Suzano's sales and revenue in the second quarter of 20257.8.2025 04:17:00 CEST | Press release

Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2025 (2Q25), reporting sales of 3.7 million tonnes of pulp and paper. Sales increased 28% over the same period in 2024 (2Q24), mainly reflecting the strong operational contribution of the new Ribas do Rio Pardo pulp mill, whose production started in July 2024. Net revenue in the quarter totaled R$13.3 billion, a 16% increase compared to 2Q24. The expansion of pulp production capacity in Brazil, combined with the positive contribution to paper sales from the mills recently acquired in the United States and favorable FX rates, mitigated the impact on net revenue of lower pulp prices in the global market compared to 2Q24. As a result, Suzano's adjusted EBITDA reached R$6.1 billion and operating cash generation totaled R$4.1 billion. Net profit totaled R$5.0 billion positively impacted by the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. Beto

Graanul - Update on the Consent Solicitation and Scheme Solicitation6.8.2025 22:22:00 CEST | Press release

Graanul: Update on the Consent Solicitation and Scheme Solicitation relating to: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and together with its subsidiaries, “Graanul”

Statement by Aviator LLC6.8.2025 16:18:00 CEST | Press release

Company successfully initiates proceedings following Georgian court victories; UK injunction preserves status quo pending trial Aviator LLC today issued a statement clarifying the nature and scope of a recent UK court ruling following public statements made by SPRIBE OU regarding interim injunction proceedings. According to Nikoloz Gogilidze, legal representative for Aviator LLC, the recent court order was an interim injunction with limited scope and commercial impact. Gogilidze highlights the key points of the proceedings, which appear to have been mischaracterized in some media reports. Nature of the Court Order: The ruling represents an interim injunction granted at a preliminary procedural stage, not a final determination on the merits of the underlying dispute. Such orders are designed to maintain the status quo pending full trial proceedings. Commercial Impact: The injunction has no practical effect as neither Aviator LLC nor its IP rights licensee had any existing plans to enter

Lenovo Brings Its Biggest-Ever Global Tech World Event to CES 2026 With an Immersive Experience at Sphere in Las Vegas6.8.2025 15:05:00 CEST | Press release

Lenovo Chairman and CEO Yuanqing Yang to deliver CES keynote on smarter AI for all at iconic venue, showcasing innovations with FIFA, Formula 1®, and a host of others at the world’s biggest tech event.Tech World CES Keynote to showcase Lenovo’s role as An Official Technology Partner of Sphere Studios Lenovo (HKSE: 992) (ADR: LNVGY) and Sphere Entertainment Co. (NYSE: SPHR) announced today that, for the first time ever, Lenovo’s annual global innovation event, Tech World, will take center stage at Sphere in Las Vegas on the opening day of CES® 2026. The 11th annual Tech World will feature Lenovo Chairman and CEO Yuanqing Yang’s CES keynote along with Lenovo’s latest product launches, innovations, proofs of concept, and the company’s AI-driven innovation strategy for the coming years. The event at Sphere, which will showcase content created exclusively for Lenovo by Sphere Studios, Sphere’s in-house immersive content studio, marks the second consecutive year that a CES keynote will be de

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye